Clinical Trial: 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Phase II Study of Gemcitabine in Transitional Cell Carcinoma of the Urothelium

Brief Summary: To investigate efficacy and safety of 2nd line GEM monotherapy after CDDP regimen for patients with transitional cell carcinoma of urothelium

Detailed Summary:
Sponsor: Eli Lilly and Company

Current Primary Outcome: Response rate

Original Primary Outcome:

Current Secondary Outcome:

• Progression-free survival
• Overall survival

Original Secondary Outcome:

Information By: Eli Lilly and Company

Dates:
Date Received: September 12, 2005
Date Started: January 2004
Date Completion:
Last Updated: November 5, 2007
Last Verified: November 2007